About Ariad Pharmaceuticals
Ariad Pharmaceuticals is a company based in Cambridge (United States) founded in 1991 was acquired by Takeda in January 2017.. Ariad Pharmaceuticals has raised $46 million across 7 funding rounds from investors including Credit Suisse and Takeda Pharmaceuticals. The company has 328 employees as of December 31, 2015. Ariad Pharmaceuticals operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter Cambridge, United States
- Employees 328 as on 31 Dec, 2015
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$118.8 M13as on Dec 31, 2015
-
Net Profit
$-231.16 M-42as on Dec 31, 2015
-
EBITDA
$-217.28 M-36as on Dec 31, 2015
-
Total Equity Funding
$46 M (USD)
in 7 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Jun 12, 2014
-
Investors
Credit Suisse
& 1 more
-
Employee Count
328
as on Dec 31, 2015
-
Acquired by
Takeda
(Jan 09, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ariad Pharmaceuticals
Ariad Pharmaceuticals has successfully raised a total of $46M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $200.0M
-
First Round
First Round
(27 Mar 1992)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2014 | Amount | Post-IPO - Ariad Pharmaceuticals | Valuation |
investors |
|
| Oct, 2006 | Amount | Post-IPO - Ariad Pharmaceuticals | Valuation |
investors |
|
| Jan, 2002 | Amount | Post-IPO - Ariad Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ariad Pharmaceuticals
Ariad Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Credit Suisse and Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Wealth management, asset management, and investment banking services are offered.
|
Founded Year | Domain | Location | |
|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ariad Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ariad Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ariad Pharmaceuticals Comparisons
Competitors of Ariad Pharmaceuticals
Ariad Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Ossium Health is focused on bioengineering for improved health.
|
|
| domain | founded_year | HQ Location |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer and genetic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ariad Pharmaceuticals
Frequently Asked Questions about Ariad Pharmaceuticals
When was Ariad Pharmaceuticals founded?
Ariad Pharmaceuticals was founded in 1991 and raised its 1st funding round 1 year after it was founded.
Where is Ariad Pharmaceuticals located?
Ariad Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Ariad Pharmaceuticals a funded company?
Ariad Pharmaceuticals is a funded company, having raised a total of $46M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $7.6M, raised on Mar 27, 1992.
How many employees does Ariad Pharmaceuticals have?
As of Dec 31, 2015, the latest employee count at Ariad Pharmaceuticals is 328.
What is the annual revenue of Ariad Pharmaceuticals?
Annual revenue of Ariad Pharmaceuticals is $118.8M as on Dec 31, 2015.
What does Ariad Pharmaceuticals do?
Ariad Pharmaceuticals is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. Its product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), A32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Also investigating Iclusig for the treatment of other cancer such as lung, biliary. Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK) to treat non-small cell lung cancer (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR) and it is developing it to treat non-small cell lung cancer.
Who are the top competitors of Ariad Pharmaceuticals?
Ariad Pharmaceuticals's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Who are Ariad Pharmaceuticals's investors?
Ariad Pharmaceuticals has 2 investors. Key investors include Credit Suisse, and Takeda Pharmaceuticals.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.